163 related articles for article (PubMed ID: 18161388)
1. Letrozole as adjuvant therapy for postmenopausal women with early breast cancer.
Russell CA
Manag Care Interface; 2007 Sep; 20(9):30-1, 36. PubMed ID: 18161388
[No Abstract] [Full Text] [Related]
2. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
3. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M
J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of a letter notification program for women with early-stage breast cancer eligible for extended adjuvant letrozole.
McArthur HL; Gelmon KA; Olivotto IA; Speers CH; Ellard SL; O'Reilly SE; Kennecke HF
J Clin Oncol; 2009 Mar; 27(9):1388-93. PubMed ID: 19237634
[TBL] [Abstract][Full Text] [Related]
5. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
Goss PE; Ingle JN; Pater JL; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Tu D
J Clin Oncol; 2008 Apr; 26(12):1948-55. PubMed ID: 18332475
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
Muss HB; Tu D; Ingle JN; Martino S; Robert NJ; Pater JL; Whelan TJ; Palmer MJ; Piccart MJ; Shepherd LE; Pritchard KI; He Z; Goss PE
J Clin Oncol; 2008 Apr; 26(12):1956-64. PubMed ID: 18332474
[TBL] [Abstract][Full Text] [Related]
7. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
8. New breast cancer drug.
Brink S
US News World Rep; 2001 Dec; 131(26):52. PubMed ID: 11793594
[No Abstract] [Full Text] [Related]
9. Letrozole better than tamoxifen in postmenopausal women.
Fricker J
Lancet Oncol; 2005 Mar; 6(3):137. PubMed ID: 15759362
[No Abstract] [Full Text] [Related]
10. Resolution of endometrial hyperplasia with adjuvant anastrozole treatment in postmenopausal breast cancer: a case report.
Stilwill SE; Cooper BC
J Reprod Med; 2007 Oct; 52(10):979-80. PubMed ID: 17977182
[TBL] [Abstract][Full Text] [Related]
11. Letrozole: a review of its use in the treatment of postmenopausal women with hormone-responsive early breast cancer.
Keating GM
Drugs; 2009 Aug; 69(12):1681-705. PubMed ID: 19678717
[TBL] [Abstract][Full Text] [Related]
12. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Geisler J; Helle H; Ekse D; Duong NK; Evans DB; Nordbø Y; Aas T; Lønning PE
Clin Cancer Res; 2008 Oct; 14(19):6330-5. PubMed ID: 18829517
[TBL] [Abstract][Full Text] [Related]
13. Huge response to letrozole in inoperable T4 breast cancer: a case report.
Di Cosimo S; Altomare V; Ferretti G; Gravante G; Rabitti C; Rea F; Arullani A; D'Aprile M
Clin Ter; 2001; 152(4):263-5. PubMed ID: 11725620
[TBL] [Abstract][Full Text] [Related]
14. Extending the benefits of adjuvant therapy in early HR+ breast cancer.
Goss PE
Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():45-52. PubMed ID: 18785006
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Generali D; Fox SB; Brizzi MP; Allevi G; Bonardi S; Aguggini S; Milani M; Bersiga A; Campo L; Dionisio R; Vergoni F; Giardini R; Dogliotti L; Bottini A; Harris AL; Berruti A
Clin Cancer Res; 2008 May; 14(9):2673-80. PubMed ID: 18451231
[TBL] [Abstract][Full Text] [Related]
16. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
17. Femara approved as first-line breast cancer therapy.
FDA Consum; 2001; 35(3):5. PubMed ID: 11458552
[No Abstract] [Full Text] [Related]
18. Letrozole in postmenopausal hormone-responsive early-stage breast cancer : a viewpoint by Laura B. Michaud.
Michaud LB
Drugs; 2006; 66(3):363-4. PubMed ID: 16526827
[No Abstract] [Full Text] [Related]
19. Effectiveness of letrozole in the breast cancer treatment continuum.
Monnier A
Breast; 2006 Feb; 15 Suppl 1():S1-2. PubMed ID: 16500234
[No Abstract] [Full Text] [Related]
20. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.
Azim AA; Costantini-Ferrando M; Oktay K
J Clin Oncol; 2008 Jun; 26(16):2630-5. PubMed ID: 18509175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
